Lentivirus Production
Lentivirus Production - Related Videos
11:42
Lentivirus Production
0 Views •
Cited by 43 •
2009
To make lentiviruses, DNA vectors are transfected into human 293 cells. After harvest and concentrating the supernatant, virus titer is determined by fluorescence expression with a flow cytometer.
03:31
Generation of Recombinant Lentivirus in Mammalian Cells
0 Views •
2026
Source: Zhang, Y., et al., Direct Reprogramming of Mouse Fibroblasts into Melanocytes. J. Vis. Exp. (2021)This video demonstrates the production and concentration of recombinant lentivirus in mammalian cells, enabling efficient gene delivery of transcription factors or other genetic elements for applications such as cellular reprogramming, functional studies, and potential therapeutic research.
09:12
Optimal Lentivirus Production and Cell Culture Conditions Necessary to Successfully Transduce Primary Human Bronchial Epithelial Cells
0 Views •
Cited by 13 •
2016
Primary human bronchial epithelial cells are difficult to transduce. This protocol describes the production of lentiviruses and their concentration as well as the optimal culture conditions necessary to achieve highly efficient transductions in these cells throughout differentiation to a pseudostratified epithelium.
04:36
Generating Lentivirus-Infected Mouse Embryonic Stem Cells
0 Views •
2026
Source: Chiarella, A. M. et. al., Repressing Gene Transcription by Redirecting Cellular Machinery with Chemical Epigenetic Modifiers. J. Vis. Exp. (2018)This video demonstrates the generation of genetically modified mouse embryonic stem cells using lentiviral transduction. Lentiviral particles deliver an antibiotic resistance marker, allowing stable genomic integration and selection of transduced cells.
11:34
Lentivirus-mediated Genetic Manipulation and Visualization of Olfactory Sensory Neurons in vivo
0 Views •
Cited by 7 •
2011
We present a lentiviral technique for genetic manipulation and visualization of single olfactory sensory neuron axon and its terminal arborization in vivo.
FAQs
The transfer plasmid carries the intended genetic payload, while packaging plasmids provide the viral proteins required for particle assembly and release. Producer cells bring these components together, allowing vector particles to form without relying on target cells to supply those functions. This division of roles separates payload delivery from the proteins needed to generate particles.
Replication incompetence means the generated vectors are designed as delivery vehicles rather than self-propagating viruses. Their role is to transfer the payload into target cells, not to produce additional vector through an ongoing replication cycle. This feature is central when lentiviral vectors are used for gene-function studies, disease models, or therapeutic development.
Because the vectors can transduce both dividing and nondividing cells, researchers can investigate genetic effects in cell populations that differ in proliferation status. Once the payload supports stable gene expression, the resulting cells can be followed for sustained effects rather than only immediate delivery. This combination broadens experimental use across gene-function studies and engineered immune-cell models.
The workflow progresses from introducing the transfer and packaging plasmids into producer cells to allowing vector particles to assemble and be released. Researchers then collect the generated material and purify the vectors before exposing target cells. These stages connect particle generation with a preparation suitable for transduction and downstream research or therapeutic development.
Lentivirus production is useful when a study requires genetic material to be delivered into target cells for gene-function analysis, disease modeling, or immune-cell engineering. In medicine, the same platform supports development of gene and cell therapies, including strategies that deliver therapeutic genes. Its value therefore spans basic investigation, disease research, and therapeutic development.
In medical research, generated vectors can modify immune cells or deliver therapeutic genes, linking laboratory vector generation with cell-based and gene-based therapeutic approaches. They also support disease models in which altered genetic material helps investigators study disease-related biology. These uses connect the production workflow to both experimental medicine and the development of potential therapeutic strategies.